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Background: Manganese superoxide dismutase (MnSOD) is a mitochondrial antioxidant enzyme that is
down-regulated in a majority of cancers. Due to this observation, as well as MnSOD0 s potent antioxidant
enzymatic activity, MnSOD has been suggested as a tumor suppressor for over 30 years. However, testing
this postulate has proven difﬁcult due to the early post-natal lethality of the MnSOD constitutive knockout mouse. We have previously used a conditional tissue-speciﬁc MnSOD knock-out mouse to study the
effects of MnSOD loss on the development of various cell types, but long-term cancer development
studies have not been performed. We hypothesized the complete loss of MnSOD would signiﬁcantly
increase the rate of tumor formation in a tissue-speciﬁc manner.
Results: Utilizing a hematopoietic stem cell speciﬁc Cre-recombinase mouse model, we created panhematopoietic cell MnSOD knock-out mice. Additionally, we combined this MnSOD knock-out with two
well established models of lymphoma development: B-lymphocyte speciﬁc Myc over-expression and
conditional pan-hematopoietic cell p53 knock-out. Mice were allowed to age unchallenged until illness
or death had occurred. Contrary to our initial hypothesis, the loss of MnSOD alone was insufﬁcient in
causing an increase in tumor formation, but did cause signiﬁcant life-shortening skin pathology in a
strain-dependent manner. Moreover, the loss of MnSOD in conjunction with either Myc overexpression
or p53 knock-out did not accelerate tumor formation, and in fact delayed lymphomagenesis in the p53
knock-out model.
Conclusions: Our ﬁndings strongly suggest that MnSOD does not act as a classical tumor suppressor in
hematological tissues. Additionally, the complete loss of MnSOD may actually protect from tumor
development by the creation of an unfavorable redox environment for tumor progression. In summary,
these results in combination with our previous work suggest that MnSOD needs to be tightly regulated
for proper cellular homeostasis, and altering the activity in either direction may lead to cellular
dysfunction, oncogenesis, or death.
& 2014 The Authors. Published by Elsevier B.V. All rights reserved.
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Introduction
In 1979, Larry Oberley and Garry Buettner outlined the free radical
theory of oncogenesis [1]. The theory stemmed from numerous
observations that the superoxide dismutase class of enzymes, particularly the mitochondrial isoform manganese superoxide dismutase
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(MnSOD), was shown to be expressed at low levels in cancers of
various cell types compared to their normal tissues of origin. The
theory frameworks three predictions in regards to the role of MnSOD
and cancer: (1) all cancers should possess decreased amounts of
MnSOD activity compared to their normal tissue counterparts, (2)
replacement of MnSOD in tumor cells should abrogate the malignant
phenotype, and (3) normal cells that lose MnSOD will in turn become
malignant. With very few exceptions, the ﬁrst two postulates have
overwhelming evidence demonstrating their validity in regards to
MnSOD and cancer. In contrast, the third postulate deﬁnes MnSOD as
a genuine tumor suppressor protein, and is the only postulate that
remains unanswered to date.
The major limitation in addressing the third prediction has
been a lack of a viable MnSOD knock-out model. Two separate
constitutive MnSOD knock-out mice strains have been developed,
and both demonstrate early post-natal lethality due to overt
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oxygen toxicity and system-wide organ failure [2,3]. These observations have elucidated the critical function of MnSOD in mammalian development, but do not address the role of MnSOD in
oncogenesis. To date, the most convincing evidence that MnSOD
acts as a tumor suppressor protein is from MnSOD heterozygous
mice. While these mice possess the same lifespan of wild-type
mice, they have signiﬁcantly more cancer (primarily lymphoma) at
the end of their life [4]. While this evidence proposes a compelling
argument for MnSOD as a tumor suppressor protein, the heterozygous mice still retain at least 50% MnSOD activity, and thus have
not addressed the hypothesis that complete loss of MnSOD
initiates tumor formation in a dose-dependent fashion and therefore acts as a classical tumor suppressor protein.
In 2002, Ikegami et al. created a conditional MnSOD knock-out
mouse utilizing Cre/loxP technology [5]. Since this time, our group
has been at the forefront of characterizing the effects of tissuespeciﬁc loss of MnSOD in an array of cell types [6–9]. We have
observed signiﬁcant phenotypes due to the loss of MnSOD
including severe immunodeﬁciency (T-lymphocytes), aberrant
iron homeostasis (pan-hematopoietic cells), and epigenetic dysregulation (liver) in several models we have developed [7–9]. To our
surprise, the complete loss of MnSOD in a tissue speciﬁc manner
alone did not cause a signiﬁcant increase in tumor formation in
any of the animal models when aged [5–8]. These data argue that
MnSOD does not act as a tumor suppressing protein in regards to
the initiation of oncogenesis, and is in direct contradiction with
the third prediction of the free radical theory of cancer. Therefore,
we hypothesized that MnSOD alone does not act as a classical
tumor suppressor, but the loss of MnSOD may exacerbate the
formation of cancer in an established model of oncogenesis.
To address this hypothesis, we crossbred our mouse model of
conditional pan-hematopoietic cell MnSOD knock-out with two
respective mouse models of lymphoma development to understand if the loss of MnSOD accelerated the formation of cancer. We
show for the ﬁrst time that the loss of MnSOD either had no effect
or prolonged lymphoma development in the respective models.
Taken together, these data strongly suggest that the loss of MnSOD
is likely not a casual event in the initiation of cancer, but instead
may be down-regulated in fully initiated cancer cells to aid in
tumor progression.
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Results and discussion
We ﬁrst examined the effects of MnSOD loss in an oncogenic
model of splenic lymphoma. We have previously demonstrated that
our hematological stem cell MnSOD knock-out is devoid of MnSOD
and possesses increased mitochondrial oxidative stress in all hematological tissues such as bone marrow, spleen, and thymus [7].
By combining our hematological stem cell knock-out of MnSOD
(MnSODL/L vav-Cre þ / ) with a model of conditional B-lymphocyte
Myc over-expression (iMyc þ / ), we assessed the rate in which these
animals developed splenic lymphoma. One-hundred percent of mice
possessing MnSOD and the iMyc allele (MnSODL/L vav-Cre  /
iMyc þ / ) developed splenic lymphoma with a mean tumor freesurvival time of approximately 45 weeks (Fig. 1A, Table 1). Surprisingly, the loss of MnSOD in conjunction with Myc over-expression
(MnSODL/L vav-Cre þ / iMyc þ / ) did not signiﬁcantly affect the rate
of tumor formation (Fig. 1A, Table 1). These data suggest the loss of
MnSOD does not act to promote tumor initiation in a Myc-driven
model of B-cell lymphoma.
It was observed that the loss of MnSOD alone (MnSODL/L vavCre þ /  iMyc  /  ) did not signiﬁcantly increase the incidence of any
type of hematological malignancy (Fig. 1A, Table 1). In contrast,
while malignancy was not increased in these animals, signiﬁcant
life-shortening severe dermatitis was observed (Table 1). We have
previously reported that the MnSODL/L vav-Cre þ /  suffer from stark
anemia, porphyria, and potential immunodeﬁciency [7,8]. At this
time we cannot rule out any of these pathologies in the contribution
to this skin pathology. Porphyria is a signiﬁcant contributor to skin
pathology, as porphyrin rings (macrocycles) are not properly
metabolized and building up in dermal tissues [13]. In our MnSOD
knock-out model, macrocycle build-up may be a major contributor
to the skin pathology, but further studies are needed to conﬁrm the

Methods
Mice homozygous for the ﬂoxed MnSOD allele (i.e. B6.CgSod2tm1, shorthand MnSODL/L) were initially bred to mice expressing Cre-recombinase under the control of the vav promoter (i.e.
B6.Cg-Tg-Vav1-iCreA2Kio/J, shorthand vav-Cre mice, Jackson Laboratories) to create hematopoietic stem cell speciﬁc knock-outs of
MnSOD [7,10]. These mice were sequentially bred to either an
oncogenic model of splenic lymphoma (i.e. B6.Cg-Tg-iMycEμ, shorthand iMyc þ /  ) or a conditional tumor suppressor knock-out
model of thymic and splenic lymphoma (i.e. FVB.129-Trp53tm1Brn,
shorthand p53L/L, NCI-Frederick Mouse Repository) [11,12]. In all
experiments, littermate controls were used to limit the effects of
genetic variation amongst strains. Upon weaning, mice were
analyzed by tail DNA to conﬁrm appropriate genotype. Mice were
observed until death with no additional challenges. Upon death or
illness, all mice were examined by full necropsy and cause of death
recorded. Kaplan-Meier with Log-Rank analysis was performed
and non-cancer deaths were appropriately censored. Causes of
death were compared between groups and analyzed by unpaired
two-tail Student0 s t-test. A p value of less than 0.01 was considered
signiﬁcant. All work was performed under the approval of the
Institutional Animal Care and Use Committee at the University
of Iowa.

Fig. 1. MnSOD loss prolongs tumor development in a p53 knock-out cancer model.
(A) Conditional hematopoietic MnSOD knock-out mice (MnSODL/L vav-Cre þ /  )
were crossed with mice over-expressing Myc targeted speciﬁcally to B-lymphocytes (iMyc þ /  ). Survival studies demonstrate no signiﬁcant changes in tumor
formation with the loss of MnSOD in combination with Myc over-expression.
(B) Conditional MnSOD knock-out mice (MnSODL/L) were crossed with conditional
p53 knock-out mice (p53L/L). Further breeding to the hematopoietic stem cell
driven Cre-recombinase mouse (vav-Cre þ /  ) creates double conditional knock-outs
for MnSOD and p53 targeted to hematopoietic tissues. Survival studies demonstrate the loss of MnSOD prolongs tumor approximately 10 weeks. Hash marks
above lines indicate censored non-tumor deaths. np o0.01 by Log-Rank analysis.
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Table 1
Cause of death in aged mice containing MnSOD, iMyc, and p53 mutations.
MnSODL/L vav-Cre  /  iMyc  / 

MnSODL/L vav-Cre  /  iMyc þ / 

MnSODL/L vav-Cre þ /  iMyc  / 

MnSODL/L vav-Cre þ /  iMyc þ / 

Dermatitis
Splenic lymphoma
Unknown
Termination of study

0 (0.0%)
0 (0.0%)
7 (8.9%)
72 (91.1%)

0 (0.0%)
38 (100.0%)n
0 (0.0%)
0 (0.0%)

28 (47.5%)n
3 (5.1%)
8 (13.6%)
20 (33.9%)

0 (0.0%)
25 (100.0%)n
0 (0.0%)
0 (0.0%)

Total

79

38

59

25

MnSODL/L vav-Cre  /  p53L/L

MnSOD þ / þ vav-Cre þ /  p53L/L

MnSODL/L vav-Cre þ /  p53 þ / þ

MnSODL/L vav-Cre þ /  p53L/L

0 (0.0%)
0 (0.0%)
0 (0.0%)
5 (10.6%)
42 (89.4%)

0 (0.0%)
4 (16.7%)n
20 (83.3%)n
0 (0.0%)
0 (0.0%)

1 (1.8%)
1 (1.8%)
0 (0.0%)
4 (7.1%)
50 (89.3%)

0 (0.0%)
7 (35.0%)n
13 (65.0%)n
0 (0.0%)
0 (0.0%)

47

24

Dermatitis
Splenic lymphoma
Thymic lymphoma
Unknown
Termination of study
Total
n

0

po 0.01 by Student s t-test compared to respective control animal (e.g. MnSOD

presence of porphyrin rings in the dermal tissues. Additionally,
C57BL/6 mice are prone to various forms of skin dermatitis, and the
loss of MnSOD in the hematopoietic system may exacerbate this
commonly observed endogenous phenotype. In 2007, Ronald
DePinho0 s group reported increased life-shortening dermatitis in a
C57BL/6 hematopoietic speciﬁc knock-out of all of the mammalian
forkhead transcription factors (FoxOs) [14]. The FoxO family of
transcription factors has been shown to control the expression of
anti-oxidant enzymes including MnSOD, and as such the knockouts displayed signiﬁcant oxidative stress comparable to our
MnSOD knock-out models. The results of our study extend these
ﬁndings showing that hematological oxidative stress appears to
have signiﬁcant effects on proper skin maintenance, though
mechanistically how this is achieved is still unclear.
Next, we examined the effect of MnSOD loss in a conditional
hematological knock-out of the tumor suppressor gene p53 (p53L/L).
We have previously reported that p53 activation was associated with
the loss of MnSOD in T-lymphocytes, and contributed to accelerated
apoptosis and a severe immunodeﬁcient phenotype [8], therefore,
we hypothesized a potential synergistic oncogenic effect with the
loss of both p53 and MnSOD. Moreover, because both MnSOD and
p53 conditional knock-out models are driven by Cre/loxP genetics,
the combination allows for the loss of both genes in the same
hematological cells as driven by the vav promoter. We ﬁrst observed
signiﬁcant and rapid thymic and splenic lymphoma development in
mice possessing only p53 knock-out (MnSOD þ / þ vav-Cre þ / p53L/L)
with a mean tumor free-survival time of approximately 18 weeks
(Fig. 1B, Table 1). Unexpectedly, the loss of both MnSOD and p53
(MnSODL/L vav-Cre þ / p53L/L) signiﬁcantly delayed tumor formation
with a mean tumor free-survival of approximately 28 weeks (Fig. 1B,
Table 1). In contrast to the previous model, the loss of MnSOD alone
(MnSODL/L vav-Cre þ / p53 þ / þ ) appeared to have no overt lifeshortening pathologies like dermatitis, which suggests a potential
strain-dependent phenotype. Overall, these data strongly imply that
MnSOD does not act as a classical tumor suppressor protein even in
conjunction with known tumor-driving mutations, and in fact the
loss of this protein may be beneﬁcial in the prevention of some types
of cancers.
Our ﬁndings presented here contradict the original free radical
theory of cancer which predicts the loss of MnSOD would cause
signiﬁcant increases in tumor formation. Our data suggest that
down-regulation of MnSOD prior to tumor formation leads to an
unfavorable environment for cancer development, and may even
protect from tumor development in certain models. One explanation
for this is simply the overwhelming oxidative stress by the loss of

56
L/L

vav-Cre

/

iMyc

20
/

or MnSOD

L/L

vav-Cre

/

p53L/L).

MnSOD causes cells to die before they become malignant. Another
possible reason for the loss of MnSOD which may delay tumor
development is the increased susceptibility to the immune response.
Once tumor cells are formed, they are often detected by the innate
immune response, in which these cells attempt to destroy the
malignant cells by an oxidative burst mechanism [15]. It could be
postulated that the loss of MnSOD may increase the susceptibility to
the innate immune response, and thus delay the development of
systemic cancer. Taken together with our previous reports, these
observations indicate the importance of a normal redox balance for
proper cellular homeostasis, and that shifting this balance by altering
MnSOD levels may lead to cellular death, dysfunction, and cancer on
either end of the spectrum (Fig. 2, Graphical Abstract). Some groups
have already attempted to exploit the redox balance by targeting
cellular antioxidants to push cancers into an extreme pro-oxidant
environment and cellular death [16–18]. While this strategy shows
signiﬁcant potential, the long term effects of inhibiting cellular
antioxidants may have detrimental effects on homeostatic normal
cells. While evidence of oxidative stress-induced hormesis has been
described [19], the ﬁne line between beneﬁcial and pathological
levels of pro-oxidants are currently not well deﬁned.

Conclusions and future work
In conclusion, we present the ﬁrst observation that complete
loss of MnSOD does not exacerbate tumor formation alone or in
combination with two well established lymphoma-causing mutations, and moreover, may prevent tumorogenesis in some
instances. Our results may be limited by the examination of the
effects of MnSOD loss solely on the hematopoietic system. While
these cells were shown to be the most susceptible to tumor
formation in the MnSOD heterozygous mice [4], the complete loss
of MnSOD has demonstrated negligible effects on tumor development. To address this limitation, we will create various conditional
knock-outs of MnSOD in conjunction with tissue-speciﬁc tumor
promoting mutations. We would hypothesize that each tissue will
demonstrate different susceptibilities to cancer formation by the
loss of MnSOD, and thus this information will prove critical in the
potential targeting of speciﬁc cancers by antioxidant or prooxidant therapy in the future.
Another potential limitation of this study is the timing of the
MnSOD knock-out. By using a hematopoietic stem cell promoter,
the loss of MnSOD occurred prior to any tumor formation caused
by either Myc over-expression or p53 loss. While our ﬁndings
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Fig. 2. Redox balance is essential in the maintenance of cellular viability. In this
study, we demonstrate that the complete loss of MnSOD prolongs the development
of p53-induced cancer. This may be due to the fact that complete loss of MnSOD
causes signiﬁcant increases in oxidative stress, and thus causes cell death as
opposed to cancer. In contrast, mice heterozygous for MnSOD marginally elevated
levels of oxidative stress, and demonstrate an increased incidence of cancer.
Conversely, excessive over-expression of MnSOD has demonstrated pathological
and toxic effects in certain systems. Taken together, a ﬁne balance is essential in
cellular homeostasis, and disruption of the redox balance in either direction may
hinder cellular viability and function.

demonstrate interesting effects on tumor initiation in these
models, these data fail to explain why a majority of tumor cell
types down-regulate MnSOD over time. To address this, we are
currently developing inducible models of MnSOD knock-out.
In this manner, tumor formation can become initiated by a known
cancer-causing mutation before temporally knocking-out MnSOD.
These models allow for examining the effects of MnSOD loss on
tumor progression, which is likely the stage of cancer that loss of
MnSOD is a major contributor.
Finally, we observed an unexpected result that loss of MnSOD
in the hematopoietic system led to increased dermatologic pathologies. This ﬁnding is highly intriguing, and the mechanism underlying the pathology is currently unknown. Numerous human skin
pathologies have been linked to immune system dysfunction, but a
connection to oxidative stress in the immune system has not been
described. We will be performing comprehensive pathologic
analyses on the skin lesions to understand their etiology, and
potentially elucidate the link between oxidative stresses in the
immune system to dermatologic maintenance. Overall, our data
extend the understanding of the contribution of the redox environment in immune system function and lymphomagenesis, and
challenge the dogma of MnSOD being causal in tumor development established more than three decades prior.
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